Tyro3 Antibody (6D6F10): sc-130073

Tyro3 Antibody (6D6F10) is a mouse monoclonal IgG1 antibody that detects Tyro3 in human samples through applications such as western blotting (WB), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Tyro3, a member of the Axl/UFO subfamily of receptor tyrosine kinases, plays a crucial role in various biological processes, including spermatogenesis, immunoregulation, and phagocytosis, making Tyro3 essential for maintaining cellular homeostasis and immune responses. Tyro3 is primarily located on the cell membrane, where Tyro3 functions as a transmembrane signaling molecule. The extracellular domain of Tyro3 is composed of two immunoglobulin-like domains and two fibronectin type III domains, which facilitate ligand binding and receptor dimerization, leading to the activation of intrinsic tyrosine kinase activity. This activation is vital for downstream signaling pathways that regulate cell growth, survival, and differentiation. Tyro3 is widely expressed in adult tissues, particularly in the brain, testis, lymphatic, and vascular tissues, highlighting Tyro3′s importance in both the central nervous system and the immune system. Additionally, Tyro3 undergoes significant post-translational modifications, including tyrosine phosphorylation and glycosylation, which are critical for functional regulation and interaction with ligands such as Protein S and Gas6, both of which are implicated in anti-coagulant processes. Anti-Tyro3 antibody (6D6F10) is an invaluable tool for researchers studying the intricate roles of this receptor in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Tyro3 Antibody (6D6F10) References:

1. TYRO3 as a potential therapeutic target in breast cancer.  |  Ekyalongo, RC., et al. 2014. Anticancer Res. 34: 3337-45. PMID: 24982338
2. Overexpression of Tyro3 and its implications on hepatocellular carcinoma progression.  |  Duan, Y., et al. 2016. Int J Oncol. 48: 358-66. PMID: 26573872
3. Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer.  |  Chien, CW., et al. 2016. Oncogene. 35: 5872-5881. PMID: 27132510
4. Tyro3 carboxyl terminal region confers stability and contains the autophosphorylation sites.  |  Shao, H., et al. 2017. Biochem Biophys Res Commun. 490: 1074-1079. PMID: 28668391
5. Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.  |  Uejima, C., et al. 2020. Anticancer Res. 40: 5593-5600. PMID: 32988883
6. Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.  |  Lu, T., et al. 2021. Cancer Immunol Res. 9: 1229-1241. PMID: 34326137
7. Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment.  |  Wang, KH. and Ding, DC. 2021. Tzu Chi Med J. 33: 250-256. PMID: 34386362
8. Loss of Tyro3 causes anxiety-relevant behavioural changes in female mice.  |  Thivisol, UMCC., et al. 2023. Brain Res. 1807: 148319. PMID: 36898476
9. TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process.  |  Shao, X., et al. 2023. Aging (Albany NY). 15: 3035-3051. PMID: 37116196
10. Tyro3 receptor tyrosine kinase contributes to pathogenic phenotypes of fibroblast-like synoviocytes in rheumatoid arthritis and disturbs immune cell balance in experimental arthritis.  |  Wang, Z., et al. 2023. Clin Immunol. 255: 109753. PMID: 37678714

The preferred Tyro3 antibody is Tyro3 Antibody (A-7): sc-166359.